Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filanesib in Relapsed/Refractory Multiple Myeloma
NCT00821249Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jan 2009
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of filanesib in multiple myeloma (MM) and plasma cell leukemia (PCL) (3 arms), sponsored by Pfizer. Primary endpoints: Maximum Tolerated Dose, Overall Response Rate and 1 more. Started Jan 2009; status: completed.
02
Drugs
filanesib
03
Conditions
multiple myeloma (MM)plasma cell leukemia (PCL)
Beyond the preview
Go deeper on NCT00821249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00821249.